Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease

Resumen

It is a single-arm, single-center, open-label, single-dose study. A total of three subjects with severe sickle cell disease (SCD), aged 12-50 years (inclusive), are planned to receive cell infusion. After successful hematopoietic stem cell engraftment is achieved in the first subject, cell infusion will be initiated for subsequent subjects.

Mostrando el original en inglés

Afecciones estudiadas

Patrocinadores